Mereo Biopharma Group Plc ADR (NASDAQ:MREO) has a beta value of 0.46 and has seen 2.01 million shares traded in the recent trading session. The company, currently valued at $259.96M, closed the recent trade at $1.63 per share which meant it gained $0.02 on the day or 1.55% during that session. The MREO stock price is -207.98% off its 52-week high price of $5.02 and 3.07% above the 52-week low of $1.58. If we look at the company’s 10-day average daily trading volume, we find that it stood at 5.98 million shares traded. The 3-month trading volume is 2.11 million shares.
The consensus among analysts is that Mereo Biopharma Group Plc ADR (MREO) is Buy stock at the moment, with a recommendation rating of 1.11. 0 analysts rate the stock as a Sell, while 0 rate it as Overweight. 0 out of 2 have rated it as a Hold, with 2 advising it as a Buy. 0 have rated the stock as Underweight. The expected earnings per share for the stock is -0.01.
Mereo Biopharma Group Plc ADR (NASDAQ:MREO) trade information
Sporting 1.55% in the green today, the stock has traded in the red over the last five days, with the highest price hit on recent trading when the MREO stock price touched $1.63 or saw a rise of 46.56%. Year-to-date, Mereo Biopharma Group Plc ADR shares have moved -56.63%, while the 5-day performance has seen it change -44.01%. Over the past 30 days, the shares of Mereo Biopharma Group Plc ADR (NASDAQ:MREO) have changed -38.30%. Short interest in the company has seen 7.96 million shares shorted with days to cover at 6.64.
Wall Street analysts have a consensus price target for the stock at $5, which means that the shares’ value could jump 67.4% from the levels at last check today.. The projected low price target is $5.0 while the price target rests at a high of $5.0. In that case, then, we find that the latest price level in today’s session is -206.75% off the targeted high while a plunge would see the stock gain -206.75% from the levels at last check today..
Mereo Biopharma Group Plc ADR (MREO) estimates and forecasts
The company’s shares have lost -56.52% over the past 6 months. Revenue growth from the last financial year stood is estimated to be 0.00%.
7 have an estimated revenue figure of 7.8M for the next ending quarter.
If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was 34.82% over the past 5 years. Earnings growth for 2025 is a modest 58.86% while over the next 5 years, the company’s earnings are expected to increase by 25.31%.
MREO Dividends
Mereo Biopharma Group Plc ADR is expected to release its next earnings report on 2025-May-13 this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.
Mereo Biopharma Group Plc ADR (NASDAQ:MREO)’s Major holders
Insiders own 0.96% of the company shares, while shares held by institutions stand at 76.57% with a share float percentage of 77.31%. Investors are also buoyed by the number of investors in a company, with Mereo Biopharma Group Plc ADR having a total of 97.0 institutions that hold shares in the company. The top two institutional holders are RUBRIC CAPITAL MANAGEMENT LP with over 15.31 million shares worth more than $55.11 million. As of 2024-06-30, RUBRIC CAPITAL MANAGEMENT LP held 2.1506% of shares outstanding.
The other major institutional holder is ADAGE CAPITAL PARTNERS GP, L.L.C., with the holding of over 11.79 million shares as of 2024-06-30. The firm’s total holdings are worth over $42.45 million and represent 1.6566% of shares outstanding.
